BioMarin Pharmaceutical (BMRN) Sees Large Volume Increase

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) saw unusually-high trading volume on Wednesday . Approximately 2,645,200 shares traded hands during trading, an increase of 151% from the previous session’s volume of 1,052,553 shares.The stock last traded at $87.16 and had previously closed at $81.05.

BMRN has been the subject of several research analyst reports. ValuEngine downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Wednesday, February 20th. Robert W. Baird set a $120.00 target price on BioMarin Pharmaceutical and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Oppenheimer reduced their target price on BioMarin Pharmaceutical from $92.00 to $81.00 in a research note on Friday, February 22nd. BidaskClub upgraded BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Thursday, February 28th. Finally, Barclays restated a “hold” rating and issued a $95.00 price target on shares of BioMarin Pharmaceutical in a research note on Sunday, February 24th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have issued a buy rating to the company’s stock. BioMarin Pharmaceutical currently has a consensus rating of “Buy” and a consensus price target of $116.00.

The company has a market cap of $14.73 billion, a PE ratio of -264.12 and a beta of 1.46. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.83 and a quick ratio of 2.76.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, April 25th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.02. The business had revenue of $400.70 million during the quarter, compared to the consensus estimate of $389.95 million. BioMarin Pharmaceutical had a negative return on equity of 2.97% and a negative net margin of 5.90%. The firm’s quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.12 EPS. Equities analysts forecast that BioMarin Pharmaceutical Inc. will post -0.06 EPS for the current year.

In other BioMarin Pharmaceutical news, CFO Daniel K. Spiegelman sold 13,473 shares of BioMarin Pharmaceutical stock in a transaction on Monday, April 1st. The stock was sold at an average price of $89.00, for a total value of $1,199,097.00. Following the completion of the transaction, the chief financial officer now directly owns 47,510 shares of the company’s stock, valued at approximately $4,228,390. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jean Jacques Bienaime sold 3,000 shares of BioMarin Pharmaceutical stock in a transaction on Thursday, February 21st. The shares were sold at an average price of $90.12, for a total value of $270,360.00. Following the completion of the transaction, the chief executive officer now directly owns 291,290 shares of the company’s stock, valued at $26,251,054.80. The disclosure for this sale can be found here. Insiders sold a total of 107,011 shares of company stock valued at $9,596,168 over the last ninety days. Insiders own 1.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Doyle Wealth Management acquired a new position in shares of BioMarin Pharmaceutical during the 4th quarter worth $26,000. Rational Advisors LLC raised its holdings in shares of BioMarin Pharmaceutical by 3,211.1% during the 1st quarter. Rational Advisors LLC now owns 298 shares of the biotechnology company’s stock worth $26,000 after buying an additional 289 shares in the last quarter. Commonwealth Bank of Australia raised its holdings in shares of BioMarin Pharmaceutical by 49.6% during the 4th quarter. Commonwealth Bank of Australia now owns 350 shares of the biotechnology company’s stock worth $29,000 after buying an additional 116 shares in the last quarter. Lindbrook Capital LLC acquired a new position in shares of BioMarin Pharmaceutical during the 4th quarter worth $30,000. Finally, PRW Wealth Management LLC acquired a new position in shares of BioMarin Pharmaceutical during the 4th quarter worth $30,000. 99.55% of the stock is owned by hedge funds and other institutional investors.

WARNING: This piece was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2019/05/15/biomarin-pharmaceutical-bmrn-sees-large-volume-increase.html.

BioMarin Pharmaceutical Company Profile (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Article: How to track put option volume

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.